Antiplatelet agent combination

This page covers all Antiplatelet agent combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Cyclooxygenase (COX) and P2Y12 receptor, PAR-1 (vorapaxar); Cyclooxygenase (aspirin); P2Y12 receptor (clopidogrel), P2Y12 receptor (clopidogrel); phosphodiesterase-3 (cilostazol).

Targets

Cyclooxygenase (COX) and P2Y12 receptor · PAR-1 (vorapaxar); Cyclooxygenase (aspirin); P2Y12 receptor (clopidogrel) · P2Y12 receptor (clopidogrel); phosphodiesterase-3 (cilostazol) · Thromboxane A2 pathway and P2Y12 receptor · Cyclooxygenase-1 (COX-1) and P2Y12 receptor

Marketed (4)

• Dual antiplatelet agent duration · Seoul National University Hospital · Cardiovascular
  Dual antiplatelet therapy combines two antiplatelet agents to inhibit platelet aggregation through different pathways, reducing thrombotic events.
• Vorapaxar, Aspirin, and Clopidogrel · Inova Health Care Services · Cardiovascular
  This combination therapy inhibits platelet aggregation through multiple pathways: vorapaxar blocks the protease-activated receptor-1 (PAR-1), while aspirin and clopidogrel inhibit different steps in platelet activation and clotting cascade.
• Clopidogrel, cilostazol · Kyunghee University Medical Center · Cardiovascular
  This combination of clopidogrel and cilostazol works by inhibiting platelet aggregation through different pathways to reduce thrombotic events.
• Dual antithrombotc therapy-1 · The First Affiliated Hospital with Nanjing Medical University · Cardiovascular
  Dual antiplatelet therapy combines two agents that work through different pathways to inhibit platelet aggregation and reduce thrombotic events.

Phase 3 pipeline (3)

• Dual Anti Platelet Therapy · Biosensors Europe SA · Cardiovascular
  Dual antiplatelet therapy combines two antiplatelet agents to inhibit platelet aggregation through different mechanisms, reducing thrombotic events.
• Intensive antiplatelet · Beijing Tiantan Hospital · Cardiovascular
  Intensive antiplatelet therapy inhibits platelet aggregation through multiple pathways to reduce thrombotic events.
• Combination lysine acetylsalicylate - clopidogrel · University Hospital, Bordeaux · Cardiovascular
  This combination inhibits platelet aggregation through two complementary pathways: lysine acetylsalicylate irreversibly blocks thromboxane A2 synthesis, while clopidogrel inhibits ADP-mediated platelet activation.